glp 1 court case Disappointing GLP-1 Results in Alzheimer's Trial: Underscores Promise (and Limits) of Single-Agent Approaches Judicial Panel Authorizes New GLP-1

21, the FDA updated its drug shortage list and labeled the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) as being resolved

The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease

Nearly half asked questions about personalizing compounded GLP-1RAs to justify continued compounding outside of a drug shortage. Continued below...

Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver ...

Zealand Pharma's agreement with Roche to jointly develop and commercialise an experimental amylin-based weight-loss treatment will create a strong obesity trea

"Our research demonstrates the power of GLP-1 therapies to transform health outcomes, with especially promising results for women," says an Aon exec.